Novo Nordisk, Eli Lilly, Dongyang Sunshine, etc. share the market of tens of billions, and the main battlefield of insulin is outside the standard!

The results of the sixth batch of national centralized drug collection (insulin special) have been implement.

After the implementation level is implemented, the economic burden of diabetic patients will be greatly reduced, and the market pattern of insulin will also chan.

Insulin is a special market, with more than 100 million patients, and its use continues and increases at a high ra.

Before centralized procurement, foreign capital accounted for nearly 70% of the insulin market in Chi.

However, the success of centralized procurement is by no means done once and for all, and the out-of-market market should not be underestimat.

Therefore, it has become a foregone conclusion that the in-bid market will gradually land, and the remaining out-of-bid market of more than 15 billion yuan will be the real battlefield for manufacturers to compete in the futu.

In addition, insulin products have developed to the third generation, such as insulin glargine, which is long-acting, has no peak blood concentration, and can steadily lower the blood sugar of patien.

The actual situation also proves the above judgme.

If pharmaceutical companies want to be invincible in the future competition, they must judge the situation and achieve "close defense and long attac.

Second, we must balance the relationship between the market and profi.

Of course, in the face of the same centralized procurement of insulin, foreign-funded enterprises have been hit harder and more conservative in strategy: some start laying off employees, and the best case is to do nothi.

This is the first national centralized procurement of biological drugs and biosimila.